Lymphoma Clinical Trials

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

The purpose of this study is to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free ...

This is a multi-center Phase 1/2 open label trial of G100 in patients with low grade NHL. G100 is composed of glucopyranosyl lipid A in a stable emulsion (GLA-SE) and is a potent TLR4 (toll-like receptor-4 agonist. In this study, G100 will be administered by direct injection (intratumorally) into tumors ...

The purpose of this study is to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab. Purpose of the study is also ...

People with Diffuse Large B Cell or Non-Hodgkin Lymphoma are asked to participate in a research study being conducted by Montefiore Medical Center.

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).

The purpose of this study is to compare INCB050465 with idelalisib for objective response rate (ORR) in subjects with relapsed or refractory follicular lymphoma (FL).

The ATR(ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given ...

This is an observational (non-interventional), multi-center study that will prospectively enroll patients diagnosed with, and treated for Hodgkin lymphoma. Data collection will include extraction of medical records via case report forms, self-administered patient-reported outcome questionnaires, and tissue samples (archival and newly obtained) for molecular profiling. Treatment decisions will be determined ...

The purpose of this study is to evaluate the safety/tolerability and efficacy of INCB039110 in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)